TY - JOUR

T1 - Behandling af svær astma med biologiske lægemidler hos børn og unge

AU - Spangenberg, Katrine Bredsdorff

AU - Bødtger, Uffe

AU - Hansen, Kirsten Skamstrup

AU - Chawes, Bo

PY - 2019

Y1 - 2019

N2 - Prerequisites for successful treatment of severe asthma in children and adolescents with biological drugs are: 1) systematic assessment, excluding and treating other causes of lack of asthma control, 2) immunological phenotyping of the patient, and 3) choice of biological drug targeting the specific disease mechanism. Anti-immunoglobulin (Ig) E and anti-interleukin (IL)-5 have a clinically relevant effect reducing exacerbation rate, but there is still a need for studies in children and adolescents being treated with anti-IgE and anti-IL-5 as well as newer biological drugs, which affect lung function, asthma control and quality of life.

AB - Prerequisites for successful treatment of severe asthma in children and adolescents with biological drugs are: 1) systematic assessment, excluding and treating other causes of lack of asthma control, 2) immunological phenotyping of the patient, and 3) choice of biological drug targeting the specific disease mechanism. Anti-immunoglobulin (Ig) E and anti-interleukin (IL)-5 have a clinically relevant effect reducing exacerbation rate, but there is still a need for studies in children and adolescents being treated with anti-IgE and anti-IL-5 as well as newer biological drugs, which affect lung function, asthma control and quality of life.

KW - Adolescent

KW - Anti-Asthmatic Agents/therapeutic use

KW - Antibodies, Monoclonal, Humanized

KW - Asthma/drug therapy

KW - Biological Products/therapeutic use

KW - Child

KW - Humans

KW - Omalizumab

KW - Quality of Life

M3 - Tidsskriftartikel

C2 - 30729916

VL - 181

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

M1 - V05180364

ER -